Immune cell co-expressing IL-21 and hrCD16 chimeric receptor and application thereof

A technology of IL-21 and immune cells, applied in the direction of blood/immune system cells, receptors/cell surface antigens/cell surface determinants, genetically modified cells, etc., can solve the problem of CD16 chimeric receptor without detailed research, etc. problem, achieve the effect of enhancing ADCC function and avoiding functional impairment

Active Publication Date: 2021-10-22
SHANGHAI SINOBAY BIOTECH CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, in the prior art, there is no detailed study on the CD16 chimeric receptor containing IL-21

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune cell co-expressing IL-21 and hrCD16 chimeric receptor and application thereof
  • Immune cell co-expressing IL-21 and hrCD16 chimeric receptor and application thereof
  • Immune cell co-expressing IL-21 and hrCD16 chimeric receptor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] The construction of embodiment 1 lentiviral expression plasmid

[0093] CD16.BBz (SEQ ID NO: 9) hrCD16.BBz (SEQ ID NO: 10) and hrCD16.BBz-P2A-IL-21 genes (SEQ ID NO: 8) were synthesized by Shanghai Jierui Bioengineering Co., Ltd. and cloned into Blank lentiviral expression plasmid (pXW-EF1α-MCS-P2A-EGFP) obtained pXW-EF1α-CD16.BBz (abbreviated as pXW-CD16.BBz), pXW-EF1α-hrCD16.BBz (abbreviated as pXW-hrCD16.BBz) and pXW-EF1α-hrCD16.BBz-P2A-IL-21 (abbreviated as pXW-hrCD16.BBz-IL-21) recombinant lentiviral expression plasmid, the plasmid map is as follows figure 1 shown.

Embodiment 2

[0094] Packaging, concentration and titer determination of embodiment 2 lentivirus

[0095] 1.1 Packaging of lentivirus

[0096] Treatment of HEK293T cells: 24 hours before transfection, HEK293T cells in logarithmic growth phase were collected and seeded in 10 cm cell culture dishes (6-8×10 6 cells), the cells were grown in 10 mL of complete DMEM medium at 37 °C, 5% CO 2 Culture in a cell culture box for 18-24 hours, and transfection can be carried out when the cell density reaches above 70-90%.

[0097] HEK293T cell transfection: Add 1 mL of basic DMEM medium into a 15 mL centrifuge tube, and make the lentiviral expression plasmid (pXW-CD16.BBz, pXW-hrCD16.BBz or pXW-hrCD16.BBz-IL- 21): Packaging plasmid psPAX2: envelope plasmid PMD2.G = 1:3:1 Prepare a transfection mixture, the total amount of plasmids is 15 μg / dish. Add 30 μL of TurboFect transfection reagent at a ratio of plasmid amount (μg): transfection reagent (μL) = 1:2, incubate at room temperature for 15-20 min,...

Embodiment 3

[0102] Example 3 Infection and Expansion of T Cells

[0103] Add the lentiviral vector (LV-XW-hrCD16.BBz or LV-XW-hrCD16.BBz-IL-21) (MOI=5-10) obtained by packaging and concentrating in Example 2 to 1×10 6 In a 48-well flat-bottomed plate of pre-activated peripheral blood mononuclear cells, add the pro-infection reagent protamine sulfate and adjust the working concentration to 10 μg / mL, centrifuge at 1000×g for 90 min at 32°C, and replace with a fresh one after culturing overnight. The T cell growth medium continued to culture. Add fresh T cell growth medium every 2-3 days, and adjust the cell density to 0.5-2×10 6 cells. From 6 to 7 days after infection, the immunomagnetic beads of activated T cells were removed, and the T cells modified with hrCD16 chimeric receptor and / or IL-21 were continued to be cultured, and subsequent functional experiments could be carried out after the cells rested.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an immune cell co-expressing an IL-21 and hrCD16 chimeric receptor, and the hrCD16 chimeric receptor comprises: (1) an extracellular recognition domain; (2) an extracellular spacer region; (3) a transmembrane area; (4) an intracellular signal transduction domain; optionally, the chimeric receptor further comprises (5) one or more co-stimulatory signaling domains; and / or (6) one or more cytokine receptor signaling domains. The invention also provides a combination comprising the immune cell and a tumor antigen targeting antibody or a viral antigen targeting antibody. The immune cell co-expression IL-21 provided by the invention not only can efficiently kill different types of tumor cells / virus infected cells, but also can act on para-line immune cells, and starts endogenous anti-tumor / virus immune response at the same time.

Description

technical field [0001] The invention belongs to the field of biotherapy, and relates to an immune cell co-expressing IL-21 and hrCD16 chimeric receptors and its application in the preparation of medicines for treating cancer or viral infectious diseases. Background technique [0002] At present, there are still many limitations in the clinical application of classic cancer treatment options such as surgery, radiotherapy and chemotherapy. Surgical resection can only be applied to primary tumor lesions but is helpless for multiple metastatic cancer lesions; radiotherapy is mostly not suitable for advanced and radiotherapy Patients with insensitive tumors; chemotherapy has poor tumor specificity, is often accompanied by a variety of adverse side effects, and is not suitable for patients with chemotherapy-resistant tumors. In recent years, a new type of tumor immunotherapy has gradually entered people's field of vision, that is, chimeric antigen receptor T cell therapy (Chimeric...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): C12N5/10C12N15/62C12N15/867C07K19/00A61K39/00A61K39/395A61K39/42A61P35/00A61P31/12
CPCC12N5/0636C07K16/283C07K14/7051C07K14/54C07K16/303C07K16/10C12N15/86A61K39/42A61K39/39558A61P35/00A61P31/12C12N2510/00C12N2740/15043C07K2319/02C07K2319/03C07K2319/33A61K39/4611A61K2239/53A61K39/4631A61K39/46444A61K39/464411A61K2300/00A61K39/395C07K19/00C12N5/10C12N15/62C12N15/867C07K14/70535C12N5/06C07K16/08
Inventor徐建青张晓燕廖启彬丁相卿
OwnerSHANGHAI SINOBAY BIOTECH CO LTD